We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oncolytics Biotech® Inc. Collaborators to Present Phase II Sarcoma Trial Results at CTOS Annual Meeting
News

Oncolytics Biotech® Inc. Collaborators to Present Phase II Sarcoma Trial Results at CTOS Annual Meeting

Oncolytics Biotech® Inc. Collaborators to Present Phase II Sarcoma Trial Results at CTOS Annual Meeting
News

Oncolytics Biotech® Inc. Collaborators to Present Phase II Sarcoma Trial Results at CTOS Annual Meeting

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncolytics Biotech® Inc. Collaborators to Present Phase II Sarcoma Trial Results at CTOS Annual Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The poster presentation, entitled “A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung” will be delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita’s team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.
Advertisement